Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.42 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200314 | 1.00 | KMT2A (0.44) | KMT2AL3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL2201503 | 0.99 | KMT2A (0.43) | KMT2AL3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL2201497 | 0.99 | KMT2A (0.43) | KMT2AL3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL2200600 | 0.93 | KMT2A (0.46) | KMT2AL3MBTL1MEN1MAPT | |
| SCHEMBL2200597 | 0.93 | KMT2A (0.46) | KMT2AL3MBTL1MEN1MAPT | |
| SCHEMBL2200656 | 0.92 | EPHX2 (0.47) | KMT2AL3MBTL3L3MBTL1MEN1EPHX2 | |
| SCHEMBL2200653 | 0.92 | EPHX2 (0.47) | KMT2AL3MBTL3L3MBTL1MEN1EPHX2 | |
| SCHEMBL12429457 | 0.92 | KMT2A (0.40) | KMT2AL3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL2202742 | 0.88 | KMT2A (0.50) | KMT2AL3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL2200192 | 0.88 | MCHR1 (0.42) | KMT2AL3MBTL1MEN1EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | KMT2A 4057/4885L3MBTL3 4146/4885L3MBTL1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.